IC
RLMD icon

Innealta Capital’s Relmada Therapeutics RLMD Stock Holding History

Innealta Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5
Closed -$15 – 1349
2024
Q2 		$15 Buy
+5
New +$18 ﹤0.01% 1813

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Innealta Capital's RLMD Position: Q3 2024 in Review

Innealta Capital sold out of Relmada Therapeutics (RLMD) in Q3 2024, closing a stake of 5 shares — an estimated $15 sold.

Innealta Capital first reported a position in RLMD in Q2 2024 and held it in 1 quarter. The position peaked at $15 in Q2 2024. 69 funds tracked by Wall St. Rank hold RLMD as of Q3 2024.

  • Innealta Capital reported no remaining Relmada Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 5 Relmada Therapeutics shares in Q3 2024, an estimated $15.
  • Innealta Capital first reported a position in Relmada Therapeutics in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Relmada Therapeutics position peaked at $15 in Q2 2024.
  • 69 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.